Publications by authors named "A Minson"
Background: Bispecific T-cell engaging antibodies (BsAbs) are novel agents used to treat B-cell non-Hodgkin lymphoma (B-NHL); these agents demonstrate a different toxicity profile compared with standard chemoimmunotherapy.
Objective: To describe common adverse events (AEs) experienced by patients with B-NHL during BsAb treatment.
Methods: MEDLINE, EMCARE, and EMBASE were searched for relevant studies.
Article Synopsis
- The study focused on patients with aggressive B-cell non-Hodgkin lymphoma who experienced relapse after treatment with glofitamab, finding a poor prognosis and low response rates to further therapies.
- On average, patients had a median overall survival of just 4.1 months after their condition progressed, indicating a significant challenge in treatment outcomes.
- Notably, 59% of patients showed loss of the CD20 marker at relapse, suggesting a need for further research on CD20 loss mechanisms and exploration of new treatments that do not target CD20.